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doi:10.1016/j.jds.2010.11.004Abstract Background/purpose: Various treatment regimens have been attempted to
improve oral lichen planus (OLP) lesions; however, a complete cure has not been found. The
most commonly employed and useful agents for treating OLP are topical corticosteroids.
The aim of this study was to determine if the use of prednisolone plus traditional medicinal
herbs could improve OLP symptoms, reduce recurrent severity, and prolong the time to
flare-up, thus providing evidence for future prospective randomized clinical trials.
Materials and methods: A retrospective study of 78 patients with OLP was conducted. The
resources of 2 hospital departments (Oral and Maxillofacial Surgery and Chinese Medicine)
were combined to treat these patients. Thirty OLP patients (group A) were given a low dose
(20 mg/d) of prednisolone plus 3 medicinal herbs (gan-lu-yin, jia-wei-xiao-yao-san, and zhi-
bai-di-huang-wan), 26 OLP patients (group B) were administered prednisolone alone, and 22
OLP patients (group C) were administered the medicinal herbs only. Differences among the
patient groups were compared after a 4-week treatment course and after follow-up observa-
tions which occurred at 6 and 12 months.t of Chinese Medicine, Chang Gung Memorial Hospital-Kaohsiung Memorial Center, Chang Gung
-Pei Road, Niao-Sung Township, Kaohsiung County 833, Taiwan. Tel.: þ886 928399307.
h.org.tw (Y.-C. Hung).
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210 C.T. Chiu et al.Table 1 Constituent herbs of G
Herbal medicine Gan-lu-yin
Ingredients Radix et Rh
Rehmannia
Tuber Ophi
Fructus Cit
Radix Glyc
Herba Arte
Folium Erio
Herba Arte
Radix Scut
Radix et Rh
Radix Aspa
Corn starchResults: The 24 patients (87.7%) in group A experienced no symptom recurrence of OLP within
6 months of follow-up, and neither did 10 patients (38.5%) in group B nor 8 patients (36.4%) in
group C. Likewise, 17 patients (56.7%) in group A had no recurrence of OLP at 1 year, and
neither did 7 patients (27.8%) in group B nor 6 patients (27.3%) in group C. The average time
to flare-up for group A (within 1 year) was 30.9 7.4 weeks, while those for groups B and C
were 19.5 5.7 and 20.8 5.0 weeks, respectively. The times to flare-up for groups A versus
B and A versus C significantly differed. With the exception of 2 patients with mild oral candi-
diasis in group A (6.7%), no other obvious side-effects or complaints were reported. The recur-
rent OLP severity also significantly differed for groups A versus B and A versus C.
Conclusion: Our results suggest that treatment consisting of prednisolone plus traditional
medicinal herbs can improve OLP symptoms, relieve pain, reduce recurrent severity, and
increase the disease-free period. The benefits of combined therapy for OLP should be investi-
gated by conducting a prospective randomized clinical trial in the future.
Copyright ª 2010, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Oral lichen planus (OLP) is a T cell-mediated chronic inflam-
matory disorder affecting the stratified squamous epithe-
lium.1 The most common type of OLP lesions observed is
atrophic-erosive (89.7%).2 The atrophic and erosive forms can
cause symptoms ranging from a burning sensation to severe
pain, and can interferewith life.3 Various treatment regimens
were attempted to improve refractory atrophic-erosive OLP
lesions, but a completecurehasnot beenachieved.4 Themost
commonly employed and useful agents for treating OLP are
corticosteroids, among which prednisolone is widely avail-
able.5However,one-thirdofOLPpatients treatedwith topical
corticosteroids develops secondary candidiasis which neces-
sitates treatment.6 The potential toxicity of prednisolone
requires that it be used only when necessary, at the lowest
dose possible, and for the shortest duration.7
Use of alternative medicines or unconventional medicines
is on the rise worldwide.8,9 Therefore, interest in the use of
such alternative medicines for managing symptoms of OLP
has also increased. Chinese herbal medicines are generally
considered to be capable of greater improvements in
immune function with fewer side-effects. In East Asia,
especially in China and Taiwan, traditional medicines are
often used to treat ulcers and chronic inflammation of the
oral mucosa, among which gan-lu-yin, jia-wei-xiao-yao-san,an-lu-yin, Jia-wei-xiao-yao-san,
Jia-w
izoma
e Preparata
Radix
Rhizo
Adix P
opogonis
ri immaturus
yrrhizae preparata
misiae Scopariae
botryae
misiae Scopariae
ellariae
izoma Rehmanniae
ragi
Radix
Poria
Radix
Corte
Fruct
Rhizo
Herba
Cornand zhi-bai-di-huang-wan are widely available (Table 1).
These 3 commercial herbal formulas have been used by
numerous patients for many years with no obvious adverse
effects, and have also beenused toenhance ormodulate cell-
mediated and humoral immunities. The use of both tradi-
tional and Western medicines may reduce the side-effects of
the latter and may intensify the medicinal effects. Several
papers10e13 compared (1) herbal medicine, (2) steroid, and
(3) combined-therapy efficacies for separately treating OLP;
however in this study, we compared 3 treatment modalities,
and also demonstrated a unique analysis that focused on the
severity and duration ofOLPrecurrence. The aimof this study
was to determine if the use of prednisolone plus medicinal
herbs could improve OLP symptoms, reduce recurrence
severity, and prolong the time to flare-up. Few studies have
researched these issues.
Materials and methods
Data collection and definitions
A retrospective study of 78 patients with the atrophic or
erosive type of OLP was carried out in the Department of
Oral and Maxillofacial Surgery, and Department of Chinese
Medicine between 2004 and 2007. All patients had been
clinically and pathologically diagnosed with atrophic orand Zhi-bai-di-huang-wan.
ei-xiao-yao-san Zhi-bai-di-huang-wan
Angelicae sinensis Radix et Rhizoma
Rehmanniae Preparatama Atractylodis macrocephalae
aeoniae alba
Blupleuri
Glycyrrhizae preparata
x Moutan
us Gardeniae
ma Ziniberis preparata
Menthae
starch
Corni Fructus
Poria
Dioscorea Opposita
Cortex Moutan
Alisma Orientale
Anemarrhrnae Rhizoma
Cortex Phellodendri
Corn starch
Prednisolone plus herbal medicine for OLP 211erosive-type OLP, and all patients had symptoms such as
roughness, a burning sensation, and pain. In order to ensure
a proper diagnosis and prevent inter- and intra-observer
differences, we developed a proposal for the clinicopatho-
logical diagnostic criteria for OLP. A set of clinical and
histopathologic diagnostic criteria, with both inter- and
intra-observer agreement, was validated for this study. If
patients were only clinically diagnosed with OLP, but it was
not proven pathologically, then they were not included in
the study. Patients were fully instructed about the treat-
ment procedures, care, follow-up examinations, and alter-
native treatment options. Each patient signed a consent
form according to the Declaration of Helsinki. With respect
to each examination, any adverse effect or discomfort
related to the therapy was documented. In these 78
patients, 30 patients (group A, 10 males and 20 females)
were treated with 20 mg prednisolone/day (5 mg q.i.d.) plus
herbal medicine (4 g gan-lu-yin q.i.d., 4 g zhi-bai-di-huang-
wan q.i.d., and 4 g jia-wei-xiao-yao-san q.i.d.; the powder
was dissolved in water and administered orally) for 4 weeks.
Twenty-six patients (group B, 8 males and 18 females) were
treated with the same regimen for 4 weeks without the
medicinal herbs. These patients did not simultaneously
accept herbal medicinal treatment because of individual
factors such as time, economic factors, or a rejection of the
taste of the herbal medicine. Twenty-two patients (group C,
6 males and 16 females) were treated with medicinal herbs
only. These patients were accustomed to traditional medi-
cine for treating oral ulcers, or had doubts about the side-
effects of Western medicine, and were therefore only
willing to accept the traditional medicinal treatment.
Outcome measures
The gender, age, medical history, symptoms, type,
severity, sites of the lesions, and disease duration were
recorded. A symptomatology score of pain was obtained
using a visual analogue scale (VAS: 0e10). OLP lesions were
scored according to the criterion scale described and
modified by Thongprasom et al.14:
 Score 5: white striae with an erosive area of >1 cm2;
 Score 4: white striae with an erosive area of <1 cm2;
 Score 3: white striae with an erythematous area of
>1 cm2;
 Score 2: white striae with an erythematous area of
<1 cm2;
 Score 1: mild white striae only; and
 Score 0: no lesions, normal mucosa.
If the OLP lesions occurred on multiple sites of the oral
mucosa, the most highly affected area was recorded. After
treatment, patients were examined at weeks 2, 4, 6, and 8,
and then every month for 12 months. At each visit, the pain
score and disease score were recorded. Complete resolu-
tion of clinical signs was defined as the disappearance of all
atrophic/erosive lesions and the total lack of white striae
(OLP score 0). If a patient suffered from multiple lesions in
the mouth, all lesions had to have been completely healed.
Complete resolution of all symptoms was defined as
a normal mucosa and the absence of any discomfort, cor-
responding to a VAS score of 0. For monitoring any adverseeffects of prednisolone and in order to allow professional
decisions as to the patients’ cortisol level control or
management, we usually consulted and followed instruc-
tions given by the patient’s medical physician. Blood
cortisol levels of patients were monitored prior to medical
treatment and then during each visit. A morning visit was
required by each patient, and patients were requested to
check the cortisol level (08:00) prior to the consultation. In
case the patient’s cortisol level exceeded the normal range
(6e23 mg/dL) during treatment, the treatment was
stopped, and the physician was consulted. If the patient
was unavailable to cooperate, it was still important for the
physician to closely monitor, based on the clinical signs and
symptoms, any adverse reactions of prednisolone, such as
edema, hypertension, suppression of the hypothalamic-
pituitary-adrenal axis, Cushing syndrome, etc.
Statistical analyses
Analysis of variance (ANOVA) and Scheffe’s multiple
comparisons were used to determine whether there was
a significant difference in the age and recurrence time of
OLP among the groups. The Wilcoxon signed-rank test was
used to determine whether there was a significant differ-
ence in indices and pain scores before and after therapy in
the 3 groups. The KruskaleWallis H test and ManneWhitney
U-test were used to analyze if there were significant
differences in the recurrence severity among the groups.
Results
At the baseline, differences in the age and OLP index
among the 3 groups of patients were statistically insignifi-
cant (Tables 2e4). Therefore, we were able to conduct
further comparisons and analyses among the 3 groups after
treatment. Significant differences in the before and after
therapy OLP indices, and the before and after pain scores
of the 3 groups were found, as assessed by the Wilcoxon
signed-rank test (P< 0.001) (Table 5). The nonparametric
KruskaleWallis test and ManneWhitney U-test, which were
used to analyze the OLP index when recurrent in groups A
versus B and A versus C, significantly differed (PZ 0.000,
0.003) (Table 4). The 24 patients (87.7%) in group A expe-
rienced no symptom recurrence of OLP within 6 months of
follow-up, and neither did 10 patients (38.5%) in group B
nor 8 patients (36.4%) in group C. Likewise, 17 patients
(56.7%) in group A had no recurrence of OLP within 1 year,
and neither did 7 patients (27.8%) in group B nor 6 patients
(27.3%) in group C. The average time to flare-up in group A
(within 1 year) was 30.90 7.4 weeks, while that for group
B was 19.5 5.7 weeks and 20.8 5.0 weeks for group C.
Times to flare-ups for groups A versus B and A versus C
significantly differed (ANOVA and Scheffe’s post-hoc test,
PZ 0.000) (Table 3). Plasma cortisol levels and systemic
conditions were monitored in patients using prednisolone.
None of the patients exhibited abnormal cortisol levels or
any systemic side-effects. With the exception of 2 patients
with mild oral candidiasis in each group (6.7% of group A
and 7.7% of group B), no other obvious side-effects or
complaints were reported. Patients with oral candidiasis
were also given antifungal therapy.
Table 2 Statistical descriptions of age, oral lichen planus (OLP) index, pain score, and differences in the recurrent index and
recurrence time of the prednisolone group, herbal medicine group, and prednisolone plus herbal medicine group.
Group Prednisolone Herbal
medicine
Prednisolone plus
herbal medicine
n Mean (SD) Min Max n Mean (SD) Min Max n Mean (SD) Min Max
Age (yr) 26 54.1 (10.80) 29 73 22 55.4 (12.24) 29 72 30 54.6 (10.48) 35 74
Recurrence time (wk) 19 19.5 (5.67) 10 31 16 20.8 (4.99) 12 30 13 30.9 (7.37) 20 46
n Median Min Max n Median Min Max n Median Min Max
OLP index before therapy 26 4 2 5 22 4 2 5 30 4.5 2 5
OLP index after 4 wk
of therapy
26 1 0 2 22 1 0 2 30 0.5 0 2
Recurrence OLP index 19 3 2 5 16 3.5 2 5 13 3 2 4
Difference in the index
of recurrent OLP
19 1 2 0 16 1 3 1 13 2 3 1
Pain score before therapy 26 7.25 3 10 22 7.5 3 10 30 7.25 3 10
Pain score after 4 wk
of therapy
26 0 0 4 22 1 0 3.5 30 0 0 2.5
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A large body of evidence supports a role for immune dys-
regulation in the pathogenesis of OLP, specifically involving
the cellular arm of the T cell-mediated immune system.15,16
In this research, we used 3 kinds of traditional medicine,
gan-lu-yin, zhi-bai-di-huang-wan, and jia-wei-xiao-yao-san,
which are often administered together to treat chronic
mucositis and oral ulcers in Taiwan, and are generally
considered to improve immunity and reduce the inflam-
matory response. Gan-lu-yin can enhance hypoxic toler-
ance and sedation, produce antibacterial effects, increase
the duration of antibodies in vivo, and prevent inflamma-
tion. The actions of this formula are to expel heat, remove
dampness, resolve inflammation, and clean the blood.
Recent studies showed that gan-lu-yin can relieve certain
side-effects of radiation therapy in the treatment of
nasopharyngeal cancer including soreness of the larynx,
weight loss, and decreased secretion of saliva. It is partic-
ularly effective in reducing damage to oral membranes. In
addition, it is also beneficial in improving physiological and
psychological health such as stabilizing the mood and
alleviating anxiety, improving the oral intake of solid food,Table 3 ANOVA of age and recurrence time among the prednisol
(group B), and herbal medicine group (group C). According to the
However, the recurrence time of the 3 groups significantly differe
which particular group means differed. The resulting multiple-co
that the recurrence time of patients with combined therapy was si
Variable Group n Mean St
Age Combined (group A) 30 54.60 10
Prednisolone (group B) 26 54.12 10
Herbal medicine (group C) 22 55.41 12
Recurrence
time
Combined (group A) 13 30.92 7
Prednisolone (group B) 19 19.47 5
Herbal medicine (group C) 16 20.75 4
***Differences were significant at the P< 0.01 level of significance.reducing dryness of the mouth, and relieving dyspnea.17e19
Studies investigated several constituent herbs of gan-lu-
yin, such as Radix et Rhizoma Rehmanniae Preparata,
Fructus Citri immaturus, Radix Glycyrrhizae Preparata,
Herba Artemisiae Scopariae, Folium Eriobotryae, Radix
Scutellariae, and Radix et Rhizoma Rehmanniae, and found
that they are involved in anti-inflammation, anti-histamine
release, decreased expression of cyclooxygenase (COX)-2,
and immunomodulation.20e26 Zhi-bai-di-huang-wan is
a kind of di-huang-wan. This remedy has been used for
centuries in China and was approved by the Department of
Health in Taiwan. Zhi-bai-di-huang-wan has an antipyretic
effect, and increases stamina. Most of the herbs in zhi-bai-
di-huang-wan, such as Radix et Rhizoma Rehmanniae Pre-
parata, Corni Fructus, Poria, Dioscorea Opposita, Cortex
Moutan, and Cortex Phellodendri, are described as being
anti-inflammatory and an immunosuppressant against
cellular immune responses, and able to modulate cytokine
expressions.20,27e31 The data also suggest that zhi-bai-di-
huang-wan functions directly on cytokine gene expressions
of activated peripheral blood mononuclear cells.32,33 Jia-
wei-xiao-yao-san can enhance the anti-inflammatory effect
of blood platelet inflammatory mediators such as 5-HT andone plus herbal medicine group (group A), prednisolone group
test results, the patients’ ages across groups did not differ.
d. Therefore, Scheffe’s post-hoc test was used to determine
mparison output is displayed in the last column. It was found
gnificantly longer than those of patients in the other 2 groups.
d. deviation F value P value Scheffe’s
multiple comparison
.483 0.082 0.922
.805
.242
.365 15.931 0.000*** A> B***
A> C***.660
.987
Table 4 Comparison analysis of the oral lichen planus (OLP) index before and after 4 weeks of therapy, recurrent OLP index,
and differences in the recurrence index of the prednisolone plus herbal medicine group (group A), prednisolone group (group B),
and herbal medicine group (group C). The nonparametric KruskaleWallis test was applied to test for differences across groups A,
B, and C. From the statistical results, we found only the variable of the index of recurrent OLP significantly differed across the 3
groups. In order to determine which 2 groups differed, we further used the ManneWhitney U-test to make pair-wise compar-
isons. According to the results, compared to the other 2 groups, group A had the smallest difference in the index of recurrent
OLP among the 3 groups.
Group KruskaleWallis test Chi-
squareda
P value Multiple comparison (P value)
OLP index before therapy 0.843 0.656
OLP index after 4 wk of therapy 2.913 0.233
Recurrence OLP index 5.645 0.059
Difference in the index of
recurrent OLP
16.195*** 0.000 A< B (0.000)b***
A< C (0.003)***
***Differences were significant at the P< 0.01 level of significance.
a Three groups’ comparison was performed by the KruskaleWallis test.
b Multiple comparisons were performed by the pair-wise ManneWhitney U-test.
Prednisolone plus herbal medicine for OLP 213also strengthens the suppressive effect against microor-
ganisms.34 It is an effective herbal medicinal prescription
used to treat functional dyspepsia associated with the
syndrome of liver stagnation, spleen deficiency, and
symptoms of a poor appetite, dry mouth, and bitter taste in
the mouth. It can also improve gastrointestinal movement
and has an antidepressant-like effect.34e36 Significant
treatment utility of inflammatory pain, anti-histamine
release, regulation of immune complexes, antimicrobial
effects, and immunomodulatory activities of several
constituent herbs of jia-wei-xiao-yao-san were found,
including Radix Angelicae sinensis, Rhizoma Atractylodis
macrocephalae, Adix Paeoniae alba, Radix Blupleuri, Poria,
Radix Glycyrrhizae preparata, and Cortex Moutan.37e40
Various treatment regimens such as the administration
of a systemic or topical corticosteroid, cyclosporin, reti-
noid, and/or tacrolimus were attempted to improve
refractory OLP lesions. None of the above agents used for
OLP resulted in long-term remission, and when they are
withdrawn, the disease usually recurs. As no therapy is
curative, the goal for symptomatic patients is to palliate
symptoms. The abovementioned treatments are non-
specific and directed at eliminating inflammation. They are
therefore only partially successful, and their effects are
temporary. Moreover, there are few data on long-term
therapeutic outcomes for OLP patients.41 Therefore, there
is no definitive treatment that results in long-term remis-
sion.4 Levamisole was found to have a therapeutic effect on
OLP in recent years. It was originally developed as an
antihelminthic drug, but it has attracted interest as anTable 5 Statistical analysis of the oral lichen planus (OLP) indic
therapy of the prednisolone group, herbal medicine group, and p
Group n OLP index
before
therapy
OLP index after
4 wk of t
herapy
Prednisolone 26 4 1.0
Herbal medicine 22 4 1
Prednisolone plus
herbal medicine
30 4.5 0.5
Wilcoxon signed-rank test.effective agent with immunomodulating properties that
influence a host’s cell-mediated immune mechanisms.42
Levamisole was found to restore the normal phagocytic
activity of macrophages and neutrophils, to immunomodu-
late or immunopotentiate T cell-mediated immunity, and to
potentiate the activity of human interferon and interleukin
(IL)-2.43e45 However, some side-effects such as flu-like
symptoms, granulocytopenia, and skin rashes may occur in
some patients taking levamisole.42,43
Prednisolone is a well-known, anti-inflammatory and
immunosuppressive drug that acts on lymphocytes, and
interferes with the inflammatory response. However, the
toxicity of prednisolone requires that it be used only when
necessary, at the lowest dose possible, and for the shortest
duration of time.12 Carbone et al.7 prescribed a high dose
(50 mg/d) of prednisolone for patients with OLP. They
affirmed that after 6 months of prednisolone therapy, 68.2%
of patients had experienced complete remission, and 22.7%
showed partial remission. They also found that in 50% of
patients, results were not maintained after an average
period of 8.9 months. However, 32% of those patients
experienced adverse effects from therapy. Lozada and
Miranda administered quite a high dose of prednisolone (up
to 80 mg/d), and side-effects occurred in up to 61% of
cases.4 Thongprasom et al. reported that patients given 2
years of treatment for OLP resulted in complete remission
rates of 77.3%, 21.4%, and 17.0% among patients respec-
tively administered with fluocinolone acetonide in orabase
(FAO), fluocinolone acetonide in solution (FAS), and FAS/
FAO.46 The percentages of OLP patients with orales before and after therapy, and pain scores before and after
rednisolone plus herbal medicine group.
P value Pain score
before
therapy
Pain score
after 4 wk
of therapy
P value
<0.001 7.25 0 <0.001
<0.001 7.5 1 <0.001
<0.001 7.25 0 <0.001
214 C.T. Chiu et al.candidiasis in the 3 groups after treatment were 38.3%,
14.3%, and 13.6%, respectively. Clobetasol propionate
appears to be another effective topical steroid in an
adhesive base. Carbone et al.12 also found that after 6
months of topically administered clobetasol therapy, 69.6%
of patients had experienced complete remission of symp-
toms, and 54.5% of lesions were recurrent after an average
period of 7 months. Compared to the aforementioned
therapeutic studies of steroids, the complete OLP remission
rates for patients who received prednisolone plus tradi-
tional medicinal herbs were 88.9% within 6 months and
55.6% within 1 year. With the exception of 2 patients
(representing 6.7% of study group A) who experienced slight
candidiasis infections, the [side-effect?] occurrence rate of
the combined medicinal therapy was lower than that of
patients who took other types of steroids. We demonstrate
that this corticosteroid-sparing, combination drug approach
for OLP patients seems to produce clinical control with
a lessening of the side-effects of oral candidiasis related to
long-term and high-dose administration of prednisolone.
Sun et al. also indicated that combination therapy for OLP
with prednisolone plus medicinal herbs was superior to
single therapy (prednisolone).47
Compared to non-steroid medicines such as cyclosporin,
retinoid, and tacrolimus48e50, treatment with prednisolone
plus medicinal herbs has the potential to improve OLP symp-
toms, prolong the time to flare-ups, and have fewer side-
effects of oral candidiasis. Furthermore, the cost of daily
administration of the 3 kinds of traditional herbs is aboutUS$2
per day; it is more cost-effective than systemic therapy.
However, the exact efficacy and clinical roles of prednisolone
plus herbal medicines were not convincingly demonstrated in
this study because of the lack of a blinded approach and some
statistical concerns, and only the possibility of its efficacywas
examined. Therefore, a double-blinded trial with greater
patient numbers and a placebo control to evaluate the effi-
cacy of combined medical therapy needs to be done in
a further study.This study lacks theassociating immunological
markers (such as IL-6, IL-8, or squamous cell carcinoma-
associated antigen) for evaluating the therapeutic effects.
This is also an area that requires further study.47,51,52 In
addition, further research isneededtodiscover the functional
mechanisms of the above-described traditional medicines,
and compare themwith the other useful herbal medicines for
OLP therapy.45,47
Conclusions
TreatmentofOLPwithprednisoloneplus traditionalmedicinal
herbs can improve symptoms, relieve pain, reduce recurrent
severity, and prolong the disease-free period, is more cost-
effective, and has fewer side-effects of oral candidiasis than
treatment with other medications. The benefit of combined
therapy for OLP should be investigated by conducting
a prospective randomized clinical trial in the future.
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